Argos Therapeutics Inc (ARGS) was Reiterated by FBR Capital to “Outperform” while Lowering the Price Target of the company shares to $ 13 from a previous price target of $14 . FBR Capital advised their investors in a research report released on Aug 11, 2016.
Argos Therapeutics Inc opened for trading at $4.7 and hit $5.05 on the upside on Monday, eventually ending the session at $4.9, with a gain of 2.94% or 0.14 points. The heightened volatility saw the trading volume jump to 2,56,859 shares. Company has a market cap of $127 M.
In a different news, on Jul 1, 2016, Hubert Birner (director) purchased 275,545 shares at $0.00 per share price. According to the SEC, on Jan 8, 2016, Jeffrey D Abbey (CEO) purchased 5,000 shares at $2.50 per share price. On Dec 17, 2015, Joan Winterbottom (Chief Human Resources Officer) purchased 250 shares at $1.83 per share price, according to the Form-4 filing with the securities and exchange commission.
Argos Therapeutics Inc. (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003 which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers. The Company is also developing AGS-004 its second Arcelis-based product candidate for the treatment of Human Immunodeficiency Virus (HIV). The Company is conducting a Phase III clinical trial of AGS-003 plus sunitinib/targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA) with the Food and Drug Administration (FDA). The Company has completed three clinical trials of AGS-004. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate personalized immunotherapies.